Katelyn Brown
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Diabetes Treatment and Management, Diabetes Management and Research, Metabolism, Diabetes, and Cancer, Medication Adherence and Compliance, Diet and metabolism studies
Most-Cited Works
- → Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes(2021)1,723 cited
- → Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial(2021)569 cited
- → Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon‐like peptide‐1 receptor agonists: H igher adherence and persistence with dulaglutide compared with once‐weekly exenatide and liraglutide(2017)106 cited
- → Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program(2023)49 cited
- → A Large-Scale, Multiplayer Virtual Reality Deployment: A Novel Approach to Distance Education in Human Anatomy(2023)31 cited
- → Acid-Suppressing Agents and Risk for Clostridium difficile Infection in Pediatric Patients(2015)27 cited
- → Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2)(2024)21 cited
- → Risk Factors for Transfusions Following Total Joint Arthroplasty in Patients With Rheumatoid Arthritis(2018)19 cited
- → Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies(2023)15 cited
- → Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme(2023)15 cited